Evidence map›Paper›PMID 23926329›Full record

Trial reportThe Journal of infectious diseases2013

A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia.

Ayodhia Pitaloka Pasaribu, Watcharee Chokejindachai, Chukiat Sirivichayakul, Naowarat Tanomsing, Irwin Chavez, Emiliana Tjitra, Syahril Pasaribu, Mallika Imwong, Nicholas J White, Arjen M Dondorp

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01288820 (Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia), which is not on this map. Cited by 28 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 11 pooled it
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01288820 phase3completednot on this map

Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia: 1 Year Followup

TypeinterventionalSponsorUniversity of OxfordRan2011 to 2012Enrolled331ConditionsVivax MalariaArmsDihydroartemisinin/piperaquine + primaquine, Artesunate-amodiaquine + primaquine
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 11 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Seven-day versus fourteen-day low-dose primaquine forThe Lancet regional health. Southeast Asia · 2026
    Article
  15. Effect of higher dose primaquine for the radical cure ofThe Lancet regional health. Western Pacific · 2026
    Article
  16. Article
  17. IJID regions · 2026
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Ayodhia Pitaloka PasaribuFaculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Watcharee Chokejindachai
Chukiat Sirivichayakul
Naowarat Tanomsing
Irwin Chavez
Emiliana Tjitra
Syahril Pasaribu
Mallika Imwong
Nicholas J White
Arjen M Dondorp
Mahidol University · THMahidol Oxford Tropical Medicine Research Unit · THUniversity of North Sumatra · IDMinistry of Health · ID

Funding

Wellcome Trust 089275Wellcome Trust 093956
6 · The paper itself

Abstract

backgroundA high prevalence of chloroquine-resistant Plasmodium vivax in Indonesia has shifted first-line treatment to artemisinin-based combination therapies, combined with primaquine (PQ) for radical cure. Which combination is most effective and safe remains to be established.

methodsWe conducted a prospective open-label randomized comparison of 14 days of PQ (0.25 mg base/kg) plus either artesunate-amodiaquine (AAQ + PQ) or dihydroartemisinin-piperaquine (DHP + PQ) for the treatment of uncomplicated monoinfection P. vivax malaria in North Sumatera, Indonesia. Patients were randomized and treatments were given without prior testing for G6PD status. The primary outcome was parasitological failure at day 42. Patients were followed up to 1 year.

resultsBetween December 2010 and April 2012, 331 patients were included. After treatment with AAQ + PQ, recurrent infection occurred in 0 of 167 patients within 42 days and in 15 of 130 (11.5%; 95% confidence interval [CI], 6.6%-18.3%) within a year. With DHP + PQ, this was 1 of 164 (0.6%; 95% CI, 0.01%-3.4%) and 13 of 143 (9.1%; 95% CI, 4.9%-15.0%), respectively (P > .2). Intravascular hemolysis occurred in 5 patients, of which 3 males were hemizygous for the G6PD-Mahidol mutation. Minor adverse events were more frequent with AAQ + PQ.

conclusionsIn North Sumatera, Indonesia, AAQ and DHP, both combined with PQ, were effective for blood-stage parasite clearance of uncomplicated P. vivax malaria. Both treatments were safe, but DHP + PQ was better tolerated. CLINICAL TRIALS REGISTRATION: NCT01288820.

Indexed as

AdolescentAdultAgedAmodiaquineAntimalarialsArtemisininsChildChild, PreschoolDrug CombinationsDrug Therapy, CombinationFemaleFollow-Up StudiesGenotypeHumansIndonesiaKaplan-Meier EstimateAmodiaquineamodiaquine, artesunate drug combinationAntimalarialsArtemisininsartenimolDrug CombinationspiperaquinePiperazinesPrimaquineQuinolinesIndonesiaPlasmodium vivaxprimaquineradical cure

Identifiers

PMID23926329
PMCPMC3814843
OpenAlexW2149878679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.